News
Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback